Skip to main content

Dr. David Badesch, MD

Pulmonology (Pulmonary Disease Physician)

12605 E 16th Ave
Aurora, CO 80045

Who else practices at this address →

Adams County includes primary care (2% of residents) shortage areas. About shortage areas

Call (720) 848-0000

  • Medicare participating

At a glance

Years since graduation
43
In the NPI registry since
2006
Medicare patients seen, 2024
170

Licensed in Colorado since 1987, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1983Medical school: University of Virginia School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    CO license 28171 (first issued 1987; active)
  • Hypertension Specialist Physician
    CO license 28171 (first issued 1987; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
170
Services billed
397
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes12177
Established patient office or other outpatient visit, 30-39 minutes10286
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes6031
Established patient office or other outpatient visit, 20-29 minutes4137
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes3516
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes2424

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 48 payments worth $42,210 in total to this clinician.

By company
Merck Sharp & Dohme LLC$42,210
By type
Consulting Fee$25,533
Travel and Lodging$16,150
Food and Beverage$528

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 24, 2025Merck Sharp & Dohme LLC
Nov 24, 2025
Consulting Fee
Company’s descriptionPayment made to Third Party Organization not to Physician.
$10,240
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$9,134
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Consulting Fee
Company’s descriptionPayment made to Third Party Organization not to Physician.
$5,760
Mar 17, 2025Merck Sharp & Dohme LLC
Mar 17, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$3,720
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$1,992
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$1,860
Oct 20, 2025Merck Sharp & Dohme LLC
Oct 20, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$1,628
May 28, 2025Merck Sharp & Dohme LLC
May 28, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
Jul 7, 2025Merck Sharp & Dohme LLC
Jul 7, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
Jul 2, 2025Merck Sharp & Dohme LLC
Jul 2, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
All 36 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 15, 2025Merck Sharp & Dohme LLC
Dec 15, 2025
Travel and Lodging
travel to Dallas, TX
Company’s descriptionPayment made to Third Party Organization not to Physician.
$286
Nov 24, 2025Merck Sharp & Dohme LLC
Nov 24, 2025
Consulting Fee
Company’s descriptionPayment made to Third Party Organization not to Physician.
$10,240
Nov 24, 2025Merck Sharp & Dohme LLC
Nov 24, 2025
Travel and Lodging
travel to Dallas, TX
Company’s descriptionPayment made to Third Party Organization not to Physician.
$150
Nov 14, 2025Merck Sharp & Dohme LLC
Nov 14, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind
$256
Nov 13, 2025Merck Sharp & Dohme LLC
Nov 13, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind
$382
Nov 13, 2025Merck Sharp & Dohme LLC
Nov 13, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind
$256
Oct 20, 2025Merck Sharp & Dohme LLC
Oct 20, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$1,628
Sep 29, 2025Merck Sharp & Dohme LLC
Sep 29, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands
Company’s descriptionProvided as part of a clinical research engagement.
$154
Sep 29, 2025Merck Sharp & Dohme LLC
Sep 29, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$78.18
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$9,134
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$371
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$122
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$18.54
Sep 28, 2025Merck Sharp & Dohme LLC
Sep 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$18.54
Sep 27, 2025Merck Sharp & Dohme LLC
Sep 27, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$371
Sep 27, 2025Merck Sharp & Dohme LLC
Sep 27, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Amsterdam, Netherlands
Company’s descriptionProvided as part of a clinical research engagement.
$151
Jul 28, 2025Merck Sharp & Dohme LLC
Jul 28, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
Jul 7, 2025Merck Sharp & Dohme LLC
Jul 7, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
Jul 2, 2025Merck Sharp & Dohme LLC
Jul 2, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
May 28, 2025Merck Sharp & Dohme LLC
May 28, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Consulting Fee
Company’s descriptionPayment made to Third Party Organization not to Physician.
$5,760
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$1,860
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Travel and Lodging
travel to Boston, MA
Company’s descriptionPayment made to Third Party Organization not to Physician.
$150
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$1,992
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$371
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$357
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$173
Apr 2, 2025Merck Sharp & Dohme LLC
Apr 2, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL
Company’s descriptionProvided as part of a clinical research engagement.
$71.32
Mar 28, 2025Merck Sharp & Dohme LLC
Mar 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$367
Mar 28, 2025Merck Sharp & Dohme LLC
Mar 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$184
Mar 28, 2025Merck Sharp & Dohme LLC
Mar 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$179
Mar 28, 2025Merck Sharp & Dohme LLC
Mar 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL
Company’s descriptionProvided as part of a clinical research engagement.
$92.66
Mar 28, 2025Merck Sharp & Dohme LLC
Mar 28, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$63.05
Mar 27, 2025Merck Sharp & Dohme LLC
Mar 27, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$398
Mar 17, 2025Merck Sharp & Dohme LLC
Mar 17, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$3,720
Jan 15, 2025Merck Sharp & Dohme LLC
Jan 15, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement.
$465

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $538,568 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmo…
    Merck Sharp & Dohme LLC
  • A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
    Merck Sharp & Dohme LLC
  • An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept MK-7962 Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care
    Merck Sharp & Dohme LLC
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organizati…
    Merck Sharp & Dohme LLC
  • An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
    Merck Sharp & Dohme LLC
  • A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate th…
    Novartis Pharmaceuticals Corporation
  • A phase 1 randomized doubleblind placebocontrolled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of single escalating doses of PF07868489 in healthy adult participants and repeat do…
    Pfizer Inc.
  • A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
    United Therapeutics Corporation · Completed · NCT03626688
  • A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
    United Therapeutics Corporation · Enrolling by invitation · NCT03683186
  • An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Aurora

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 7, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1275623951. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.